Hepatocellular Carcinoma Non-resectable Clinical Trial
— iHEPAROfficial title:
Individualized Dosimetry for Holmium-166-radioembolization in Patients With Unresectable Hepatocellular Carcinoma; a Multi-center, Interventional, Non-randomized, Non-comparative, Open Label, Early Phase II Study
Verified date | November 2022 |
Source | UMC Utrecht |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Patients with hepatocellular carcinoma often die from intrahepatic disease because current treatment options are limited. Local treatment using 166Ho-radioembolization (166Ho-RE) offers a safe and effective treatment. Because 166Ho-microspheres are used as a scout dose for treatment simulaton and for the actual treatment itself, a tailored approach can be used. This concept has proven to be more predictive than the 90Y-radioembolization concept (current standard-of-care), which is a based on a surrogate scout dose (i.e. 99mTc-MAA). A personal treatment plan may be used for 166Ho-radioembolization to optimize efficacy, based on scout dose distribution. However, individualized treatment planning inherently leads to treatment doses that deviate from the currently approved 'one-size-fits-all' approach (i.e. 60 Gy average absorbed dose for all patients). Therefore, safety of individualized 166Ho-RE will be evaluated first to validate safety and confirm safety thresholds. These thresholds will be used in subsequent randomized controlled studies.
Status | Recruiting |
Enrollment | 30 |
Est. completion date | November 1, 2025 |
Est. primary completion date | November 1, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: In order to be eligible to participate in this study, a subject must meet all of the following criteria: 1. Patients must have given written informed consent. 2. Female or male aged 18 years and over. 3. Diagnosis of HCC established according to the Netherlands HCC guideline criteria (in line with American AASLD criteria): nodule >1 cm in a patient at risk for HCC, with combination of arterial hypervascularity and venous or delayed phase wash-out on multiphase CT-scan or MRI-scan.2, 4 LR-5 and LR- 4 based on Liver Imaging Reporting and Data System can be included based on discretion of the principal investigator. 4. No curative treatment options (resection, transplant, or in case of solitary tumor <5 cm, RFA). 5. Life expectancy of at least 6 months. 6. ECOG Performance status 0-1 (Table 2). 7. Liver-dominant disease (maximum 5 lung nodules all =1.0 cm, solitary clinically stable adrenal metastasis, and mesenteric or portal lymph nodes all =2.0 cm are accepted). 8. Child-Pugh class A5-6 or B7. 9. At least one measurable liver lesion according to the modified RECIST criteria.(26) 10. Negative pregnancy test for women of childbearing potential. Female patients of childbearing potential should use a highly effective acceptable method of contraception (oral contraceptives, barrier methods, approved contraceptive implant, long-term injectable contraception, intrauterine device or tubal ligation) or should be more than 1 year postmenopausal or surgically sterile during their participation in this study (from the time they sign the consent form), to prevent pregnancy. Exclusion Criteria: A potential subject who meets any of the following criteria will be excluded from participation in this study: 1. Evidence of significant extrahepatic disease (MRI-scan liver and multiphase abdominal CT as well as a thoracic CT are routinely performed at screening). 2. Hepatic radiation therapy within the last 4 weeks before the start of study therapy. 3. Previous or current treatment with RE. Previous treatment with TACE, surgery, RFA, and previous or current treatment with sorafenib are allowed. 4. Major surgery within 4 weeks or incompletely healed surgical incision before starting study therapy. 5. Serum bilirubin >34.2 micromole/L (2 mg/dL). 6. Glomerular filtration rate <35 ml/min. 7. Non-correctable INR >1.5 in case of femoral approach (as opposed to radial). 8. Leukocytes <2 109/l and/or platelet count <50 109/l. 9. Significant cardiac event (e.g. myocardial infarction, superior vena cava (SVC) syndrome, New York Heart Association (NYHA) classification of heart disease =2) within 3 months before entry, or presence of cardiac disease that in the opinion of the investigator increases the risk of ventricular arrhythmia. 10. Pregnancy or breastfeeding. 11. Patients suffering from psychic disorders that make a comprehensive judgment impossible, such as psychosis, hallucinations and/or depression. 12. Patients who are declared incapacitated. 13. Previous enrollment in the present study. 14. Male patients who are not surgically sterile or do not use an acceptable method of contraception during their participation in this study (from the time they sign the consent form), to prevent pregnancy in a partner. 15. Evidence of untreated, clinically significant grade 3 portal hypertension (i.e. large varices at oesophago-gastro-duodenoscopy). In these cases, therapy with non-selective beta-blocker (propranolol) or rubber band ligation should be instituted according to accepted guidelines. In case of small varices, prophylactic propranolol is advised. 16. Portal vein thrombosis (tumor and/or bland) of the main branch (diagnosed on contrast enhanced transaxial images). Involvement of the right or left portal vein branches and more distal is accepted. 17. Untreated active hepatitis. In case of detectable viral HBV load, appropriate treatment should be instituted. 18. Transjugular intrahepatic portosystemic shunt (TIPS). 19. Body weight over 150 kg (because of maximum table load). 20. Severe allergy for intravenous contrast used (Visipaque®)(because of CT evaluation, pre-treatment angiography and treatment angiography). 21. Lung shunt >30 Gy, as calculated using scout dose SPECT/CT. Uncorrectable extrahepatic deposition of scout dose activity. Activity in the falciform ligament, portal lymph nodes and gallbladder is accepted. |
Country | Name | City | State |
---|---|---|---|
Netherlands | UMC Utrecht | Utrecht |
Lead Sponsor | Collaborator |
---|---|
UMC Utrecht | Erasmus Medical Center, Terumo Corporation |
Netherlands,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Rate of unacceptable toxicity. | For this study, unacceptable toxicity is defined as the occurrence of RE-induced liver disease, defined as a total bilirubin increase grade 3 or higher according to the CTCAE version 4.03, in combination with ascites and low albumin, in the absence of disease progression. Any (suspected unexpected) serious adverse event of (suspected unexpected) serious device effect that is possibly, probably or definitely related to study treatment will also be regarded unacceptable toxicity. | 6 months | |
Secondary | Rate of respons | Efficacy as a secondary endpoint will be based on the modified RECIST (mRECIST) response evaluation criteria. | 6 months | |
Secondary | Anti-tumor effect (alfa-fetoprotein). | Tumor marker changes will be expressed as a percentage of the pre-treatment values. | 6 months | |
Secondary | The correlation between tumor absorbed dose in Gy and rate of response according to modified RECIST. | Response will be measured according to modified RECIST. | 6 months | |
Secondary | The correlation between non-tumor liver absorbed dose in Gy and rate of unacceptable toxicity. | For this study, unacceptable toxicity is defined as the occurrence of RE-induced liver disease, defined as a total bilirubin increase grade 3 or higher according to the CTCAE version 4.03, in combination with ascites and low albumin, in the absence of disease progression. Any (suspected unexpected) serious adverse event of (suspected unexpected) serious device effect that is possibly, probably or definitely related to study treatment will also be regarded unacceptable toxicity. | 6 months | |
Secondary | EORTC Quality of Life questionnaire number C30 | The questionnaire specific manual will be used for assessment and analysis. | 6 months | |
Secondary | EORTC Quality of Life questionnaire number HCC18 | The questionnaire specific manual will be used for assessment and analysis. | 6 months | |
Secondary | Brief Pain Inventory questionnaire number BPI-SF | The questionnaire specific manual will be used for assessment and analysis. | 6 months | |
Secondary | Assessment of regional liver function | To evaluate overall and regional liver function as measured by hepatobiliary scintigraphy using 99mTc-mebrofenin SPECT/CT, pre- and post-radioembolization. | 3 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04592029 -
TACE Combined With Sintilimab and Bevacizumab for Unresectable HCC
|
Phase 1 | |
Recruiting |
NCT05953337 -
Radioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC)
|
N/A | |
Not yet recruiting |
NCT03283956 -
Safety and Efficacy of dRug-ElutiNg beADs Trans-arterial chemoEmbolization for Hepatocellular Carcinoma in Taiwan
|
N/A | |
Recruiting |
NCT03652467 -
The Safety and Efficacy of Deferoxamine for Treating Unresectable Hepatocellular Carcinoma
|
Phase 1 | |
Recruiting |
NCT05031949 -
Hyperbaric Oxygen Therapy Combined Camrelizumab in Patients With Advanced/Metastatic Hepatocellular Carcinoma
|
Phase 1 | |
Completed |
NCT03533920 -
Clinical Trial to Evaluate the Efficacy and Safety of UNI-DEB for Unresectable Hepatocellular Carcinoma
|
N/A | |
Recruiting |
NCT05992220 -
Atezolizumab Plus Bevacizumab Alone or Combined With External Beam Radiotherapy for HCC With Macrovascular Invasion
|
Phase 2 | |
Not yet recruiting |
NCT05057104 -
Non-inferiority Study of Unresectable Hepatocelluar Carcinoma Receiving Stereotactic Radiotherapy Combined With Hepatic Arterial Chemoembolization Compared With Conversion Hepatectomy
|
||
Completed |
NCT04599777 -
TACE Combined With Sorafenib and Tislelizumab for Advanced HCC
|
Phase 2 | |
Completed |
NCT04599790 -
TACE Combined With Lenvatinib and Sintilimab for Advanced HCC
|
Phase 2 | |
Recruiting |
NCT02967887 -
Evaluation of Hepatic Arterial Infusion of Cisplatin and 5-FU in Biomarker Stratified HCC
|
Phase 2 | |
Recruiting |
NCT05608213 -
Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC
|
Phase 3 | |
Recruiting |
NCT05608200 -
Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC
|
Phase 3 | |
Completed |
NCT04926376 -
Safety and Effectiveness of Eye90 Microspheres™ in the Treatment of Unresectable HCC and mCRC
|
N/A | |
Recruiting |
NCT06133062 -
Atezolizumab and Bevacizumab With Proton Radiotherapy for Unresectable Hepatocellular Carcinoma
|
Phase 2 | |
Completed |
NCT02989922 -
A Study to Evaluate SHR-1210 in Subjects With Advanced HCC
|
Phase 2 | |
Recruiting |
NCT04273100 -
PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of HCC
|
Phase 2 | |
Withdrawn |
NCT03563170 -
QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine
|
Phase 1/Phase 2 | |
Recruiting |
NCT05390112 -
Cohort Study of Patients With Hepatocellular Carcinoma and Circulating Tumor DNA Monitoring of Chemoembolization
|
||
Recruiting |
NCT05713994 -
Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma
|